玻璃体内注射雷珠单抗治疗病理性近视合并脉络膜新生血管疗效观察

发布时间：2017-12-31 09:23

本文关键词：玻璃体内注射雷珠单抗治疗病理性近视合并脉络膜新生血管疗效观察　出处：《眼科新进展》2015年11期 　论文类型：期刊论文

【摘要】：目的观察玻璃体内注射雷珠单抗治疗病理性近视合并脉络膜新生血管(choroidal neovascularization,CNV)的临床疗效及安全性。方法回顾性分析18例18眼病理性近视患者的临床资料。玻璃体内注射雷珠单抗0.5 mg(0.05 mL),术后每个月随访时行最佳矫正视力(best corrected visual acuity,BCVA)、眼底彩照、光学相干断层扫描(optical coherence tomography,OCT)检查,术后1个月、3个月、6个月随访时行眼底荧光血管造影(fluorescence fundus angiography,FFA)检查。随访过程中发现CNV部分闭合或持续渗漏者则再次予以玻璃体内注射雷珠单抗。比较治疗前后BCVA、OCT、眼底彩照及FFA检查结果 ,观察其临床疗效及安全性。结果术后1个月、3个月、6个月随访时,BCVA均较术前明显提高(F=11.354,P0.05);黄斑中心凹厚度均较术前明显降低(F=4.242,P0.05)。术后6个月随访时,16眼视力提高2行以上,2眼视力稳定;眼底彩照示所有患眼黄斑区出血吸收,FFA检查示14眼CNV完全闭合,4眼大部分闭合。玻璃体内注射雷珠单抗平均次数为2.56次,其中3眼行1次,8眼行2次,5眼行3次,2眼行4次。随访期间所有患者均未出现眼部及全身并发症。结论玻璃体内注射雷珠单抗治疗病理性近视合并CNV是安全有效的。
[Abstract]:Objective To observe the effect of intravitreal injection of the treatment of pathologic myopia choroidal neovascularization (choroidal neovascularization, CNV) the clinical efficacy and safety. Methods: a retrospective analysis of clinical data of 18 cases of eye myopia patients. 18 intravitreal injection of anti mg 0.5 single ray beads (0.05 mL), after a month of follow-up when the best corrected visual acuity (best corrected visual acuity, BCVA), fundus and optical coherence tomography (optical coherence tomography, OCT), 1 months after surgery, 3 months, 6 months follow-up of fundus fluorescein angiography (fluorescence fundus angiography, FFA) examination. Part CNV is closed or persistent leakage again to intravitreal injection of ranibizumab found during follow-up. Before and after the treatment, BCVA, OCT, FFA and fundus examination results, to observe the clinical efficacy and safety. Results after 1 months, 3 Month, 6 months of follow-up, BCVA were significantly increased (F=11.354, P0.05); foveal thickness decreased (F=4.242, P0.05). After 6 months of follow-up, visual acuity of 16 eyes increased more than 2 lines, 2 eyes remained stable; fundus macular area all eyes bleeding absorption, FFA showed CNV in 14 eyes 4 eyes completely closed, most closed. Intravitreal injection of an average of 2.56 times, of which 3 eyes underwent 1 times, 2 times in 8 eyes, 5 eyes of 2 eyes of 3 times, 4 times. During the follow-up period, all patients had no ocular and systemic complications. Conclusion intravitreal injection of ranibizumab treating pathological myopia CNV is safe and effective.

【作者单位】：达州市中心医院眼科;
【分类号】：R778.11;R773.4
【正文快照】： 病理性近视的特点是眼轴不断增长、脉络膜萎缩和漆裂样纹。脉络膜新生血管(choroidal neovascularization,CNV)是病理性近视引起视力丧失的一个重要原因。据统计,高达10%的病理性近视患者发展为CNV[1];在发达国家,病理性近视CNV是50岁以下患者视力丧失的一个主要原因。大量的

【共引文献】